JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...
JMP Securities reiterated its Market Outperform rating on AN2 Therapeutics (NASDAQ:ANTX) shares, maintaining a $5.00 price target, representing significant upside from the current price of $1.14.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback